Vimarsana
Biggest News Aggregation in the World

Page 11 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022 - Vimarsana News

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

18.02.2022 - Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to ...

Atopic Dermatitis Underrecognized in Patients of Color - Vimarsana News

Atopic Dermatitis Underrecognized in Patients of Color

Efforts are underway to use more patient-reported outcomes in trials and to equip doctors to recognize and treat the disease in diverse patient populations.

FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis - Vimarsana News

FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis

Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis - Vimarsana News

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

LEO Pharma Announces FDA Approval of Adbry (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis - Vimarsana News

LEO Pharma Announces FDA Approval of Adbry (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis

Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022. Tralokinumab is marketed outside of the U.S. under the